Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease

Research output: Contribution to journalReview articlepeer-review

113 Scopus citations

Abstract

The treatment of inflammatory bowel disease (IBD) - ulcerative colitis (UC) and Crohn's disease (CD) - has evolved beyond surgery with the introduction of biologic agents, primarily antibodies against mediators of inflammation and cell attraction. Anti-tumor necrosis factor (TNF) agents have been the first line treatment for moderate to severe ulcerative colitis and Crohn's disease for more than 15 years. During that time much has been learnt about how best to use these agents. This review will assess the evidence on how to optimize the use of anti-TNF agents; when and how to start treatment; how to monitor treatment and when to de-escalate it; and the potential adverse effects of these drugs. New and emerging treatments such as anti-attractants, anti-interleukins, and Janus kinase (JAK) inhibitors will also be discussed.

Original languageEnglish
Article numberj2505
JournalThe BMJ
Volume357
DOIs
StatePublished - 2017

Fingerprint

Dive into the research topics of 'Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease'. Together they form a unique fingerprint.

Cite this